Literature DB >> 17149701

Breast cancer mortality after screening mammography in British Columbia women.

Andrew Coldman1, Norm Phillips, Linda Warren, Lisa Kan.   

Abstract

Mammographic screening is a proven method for the early detection of breast cancer. The authors analyzed the impact of service mammographic screening on breast cancer mortality among British Columbia women who volunteered to be screened by the Screening Mammography Program of British Columbia. A cohort of women having at least one mammographic screen by Screening Mammography Program of British Columbia between the ages of 40 and 79 in the period 1988-2003 was identified. All cases and deaths from breast cancer occurring in British Columbia were identified from the British Columbia Cancer Registry and linked to the screening cohort. Expected deaths from breast cancer in the cohort were calculated using incidence and survival rates for British Columbia women not in the cohort. Adjustment was made for age and socioeconomic status of their area of residence at time of diagnosis. The breast cancer mortality ratio was calculated by dividing observed by expected breast cancer deaths. The mortality ratio (95% confidence interval) was 0.60 (0.55, 0.65) for all ages combined (p < 0.0001). The mortality ratio in women aged 40-49 at first screening was 0.61 (0.52, 0.71), similar to that in women over 50 (p = 0.90). Exclusion of mortality associated with breast cancers diagnosed after age 50 in women starting screening in their 40s increased the mortality ratio to 0.63 (0.52, 0.77), but it remained statistically significant. Correction for self-selection bias using estimates from the literature increased the mortality ratio for all ages to 0.76. Mammographic screening at all ages between 40 and 79 reduced subsequent mortality rates from breast cancer. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17149701     DOI: 10.1002/ijc.22249

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Breast cancer screening panels continue to confuse the facts and inject their own biases.

Authors:  D B Kopans
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

3.  Arguments against mammography screening continue to be based on faulty science.

Authors:  Daniel B Kopans
Journal:  Oncologist       Date:  2014-02

4.  More misinformation on breast cancer screening.

Authors:  Daniel B Kopans
Journal:  Gland Surg       Date:  2017-02

Review 5.  The wisdom trial is based on faulty reasoning and has major design and execution problems.

Authors:  Daniel B Kopans
Journal:  Breast Cancer Res Treat       Date:  2020-11-25       Impact factor: 4.872

6.  Temporal trends in the association between socioeconomic status and cancer survival in Ontario: a population-based retrospective study.

Authors:  Andrew Dabbikeh; Yingwei Peng; William J Mackillop; Christopher M Booth; Jina Zhang-Salomons
Journal:  CMAJ Open       Date:  2017-09-06

Review 7.  Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries.

Authors:  Meteb Al-Foheidi; Mubarak M Al-Mansour; Ezzeldin M Ibrahim
Journal:  Med Oncol       Date:  2013-02-19       Impact factor: 3.064

8.  Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-03-01

9.  Benefits of screening mammography.

Authors:  Wendie A Berg
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

10.  Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.

Authors:  Diana L Miglioretti; Weiwei Zhu; Karla Kerlikowske; Brian L Sprague; Tracy Onega; Diana S M Buist; Louise M Henderson; Robert A Smith
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.